British tech company Skin Analytics has received regulatory approval for an AI skin cancer detection system that uses a ...

Roth MKM analyst Jason Wittes maintained a Buy rating on Journey Medical Corp (DERM – Research Report) today and set a price target of $11.00.

Dermatologists, beauty experts, and older friends ambushed me with well-intentioned warnings about how my skin would slowly ...

Odell Beckham Jr. (OBJ) and his dermatologist discuss his experience with seb derm, or seborrheic dermatitis, as the Wide ...

In this Q&A, Marty Becker, DVM, Elite FFCP-V and Paul Bloom, DVM, DACVD, DABVP (Canine and Feline), Elite FFCP-III share extensive advice on how to minimize fear, anxiety, and stress in patients ...

Now available on the AISight® Platform, PathAssist Derm is an AI-assisted histopathology tool that enhances dermatopathology research workflows, ...

Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...

Journey Medical Co. (NASDAQ:DERM – Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 76,800 ...

Revoderm Pharma has announced its latest skincare line, featuring clean, dermatologist-developed products to support the skin ...

Journey Medical Corporation’s DERM share price has surged by 14.32%, which has investors questioning if this is right time to sell.